Report Type: Therapy Reports
Report Category: Oncology
Report Subcategory: Hormone Refractory or Castration Resistant, Androgen-Independent Prostate Cancer
Price: $ 2999.00
Date: July 2021

Hormone Refractory or Castration Resistant, Androgen-Independent Prostate Cancer: Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Hormone Refractory or Castration Resistant, Androgen-Independent Prostate Cancer: Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Top 50 Key Players:
Johnson & Johnson
F. Hoffmann-La Roche Ltd
Pfizer Inc
Bayer AG
Novartis AG
Merck & Co Inc
Sanofi
Abbott Laboratories
Bristol-Myers Squibb Co
AstraZeneca Plc
Amgen Inc
Gilead Sciences Inc
Boehringer Ingelheim International GmbH
Fujifilm Holdings Corp
Otsuka Holdings Co Ltd
Astellas Pharma Inc
Regeneron Pharmaceuticals Inc
Eisai Co Ltd
A. Menarini Industrie Farmaceutiche Riunite Srl
CareGroup Inc
Orion Corp
Hanmi Science Co Ltd
SRI International
Corcept Therapeutics Inc
Halozyme Therapeutics Inc
Nektar Therapeutics
Athenex Inc
Panacea Biotec Ltd
Arvinas Inc
Salarius Pharmaceuticals Inc
CTI BioPharma Corp
AnGes Inc
TBG Diagnostics Ltd
MEI Pharma Inc
Merrion Pharmaceuticals Plc
e-Therapeutics Plc
Cantex Pharmaceuticals Inc
Oncologie Inc
Bio-Cancer Treatment International Ltd
Celtek Bioscience LLC
Peking University
Metromedia Bio-Science LLC
University of Tokyo
Hebei General Hospital
NantWorks LLC
Mediolanum farmaceutici SpA
Fujifilm Holdings Corporation
Jyant Technologies Inc
DexTech Medical AB
Velacor Therapeutics Pty Ltd